Zomedica logo

ZOM - Zomedica Share Price

$0.079 -0.0  -2.2%

Last Trade - 20/10/20

Sector
Healthcare
Size
Micro Cap
Market Cap £34.2m
Enterprise Value £13.3m
Revenue £n/a
Position in Universe 4909th / 6436
Bullish
Bearish
Unlock ZOM Revenue
Momentum
Relative Strength (%)
1m +7.37%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -84.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 4.80
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Zomedica Corp revenues was not reported. Net loss decreased 45% to $7.8M. Lower net loss reflects Research and development decrease of 49% to $4.2M (expense), Labor & Related Expenses in SGA decrease of 59% to $1.5M (expense), Professional fees decrease of 40% to $573K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.14 to -$0.05.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZOM Revenue Unlock ZOM Revenue

Net Income

ZOM Net Income Unlock ZOM Revenue

Normalised EPS

ZOM Normalised EPS Unlock ZOM Revenue

PE Ratio Range

ZOM PE Ratio Range Unlock ZOM Revenue

Dividend Yield Range

ZOM Dividend Yield Range Unlock ZOM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZOM EPS Forecasts Unlock ZOM Revenue
Profile Summary

Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated January 7, 2013
Public Since October 28, 2013
No. of Shareholders: n/a
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NYSE MKT
Shares in Issue 564,051,438
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZOM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZOM
Upcoming Events for ZOM
Frequently Asked Questions for Zomedica
What is the Zomedica share price?

As of 20/10/20, shares in Zomedica are trading at $0.079, giving the company a market capitalisation of £34.2m. This share price information is delayed by 15 minutes.

How has the Zomedica share price performed this year?

Shares in Zomedica are currently trading at $0.079 and the price has moved by -75.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zomedica price has moved by -78.88% over the past year.

What are the analyst and broker recommendations for Zomedica?

Of the analysts with advisory recommendations for Zomedica, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zomedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zomedica next release its financial results?

Zomedica is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Zomedica dividend yield?

Zomedica does not currently pay a dividend.

Does Zomedica pay a dividend?

Zomedica does not currently pay a dividend.

When does Zomedica next pay dividends?

Zomedica does not currently pay a dividend.

How do I buy Zomedica shares?

To buy shares in Zomedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zomedica?

Shares in Zomedica are currently trading at $0.079, giving the company a market capitalisation of £34.2m.

Where are Zomedica shares listed? Where are Zomedica shares listed?

Here are the trading details for Zomedica:

Country of listing: United States
Exchange: ASQ
Ticker Symbol: ZOM
What kind of share is Zomedica?

Based on an overall assessment of its quality, value and momentum, Zomedica is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zomedica share price forecast 2020?

Shares in Zomedica are currently priced at $0.079. At that level they are trading at 0.537% discount to the analyst consensus target price of 0.00.

Analysts covering Zomedica currently have a consensus Earnings Per Share (EPS) forecast of -0.03 for the next financial year.

How can I tell whether the Zomedica share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica. Over the past six months, the relative strength of its shares against the market has been -57.56%. At the current price of $0.079, shares in Zomedica are trading at -55.6% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zomedica PE Ratio?

We were not able to find PE ratio data for Zomedica.

Who are the key directors of Zomedica?

Zomedica's management team is headed by:

Jeffrey Rowe - CHM
William MacArthur - EDR
Stephanie Morley - PRE
Angie Moricz - OTH
Andrea Eberle - OTH
Angy Guerrant - OTH
Jane Eagleson - IND
Thomas Robitaille - IND
Bruk Herbst - OTH
Johnny Powers - IND
Robert Cohen - CEO
Christopher MacLeod - IND
Ann Cotter - CFO
Christopher Wolfenberg - DRC
Who are the major shareholders of Zomedica?

Here are the top five shareholders of Zomedica based on the size of their shareholding:

Armistice Capital LLC Hedge Fund
Percentage owned: 2.72% (15.3m shares)
Rowe Family GST Trust Corporation
Percentage owned: 1.97% (11.1m shares)
Equidebt, L.L.C. Corporation
Percentage owned: 1.77% (10.0m shares)
Sabby Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 1.48% (8.33m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.41% (7.96m shares)
Similar to ZOM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.